个人简介

2012-present Campbell Family Assistant Professor of Cancer Research, University of Notre Dame 2009-2012 Associate Specialist, University of California, San Francisco 2003-2009 Postdoctoral Fellow, University of California, San Francisco 2003 Ph.D. in Cell and Developmental Biology, Harvard University 1995 B.S. in Biochemistry, B.S. in Molecular Biology, University of Texas, Austin Award: 2006-2010 American Cancer Society Postdoctoral Fellowship 2003-2006 Ruth L. Kirschstein National Research Service Award, NIH 1997-2000 NSF Predoctoral Fellowship

研究领域

Biochemistry

Littlepage's research program is focused on the contributions of the epithelium and surrounding stroma/microenvironment to both cancer progression and normal tissue development in the mammary gland and prostate. She has focused on three major projects: The transcription factor/oncogene Znf217 that promotes a progenitor cell phenotype, metastasis and chemoresistance during breast cancer progression MMP3/Stromelysin-1 promotion of progenitor expansion, genomic instability, DNA damage, and centrosome amplification during mammary tumor progression Matrix metalloproteinases that contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Overall, her research is grounded in understanding the mechanisms of cancer progression and in identifying therapies that prevent or reverse cancer in patients. She develops and uses integrated mouse models and genome-wide association studies to understand the contributions of specific genes in vivo at multiple points in cancer progression, spanning from normal mammary development to tumor progression and metastasis and chemotherapy resistance. She uses a combination of mouse and human xenograft in vivo models, cell culture and organotypic cultures, and systems biology approaches to study biomarkers of epithelial plasticity and to determine how these genes drive aberrations in fundamental biological processes, e.g., differentiation state, progenitor cell maintenance, metabolism, and genomic integrity. She also is identifying targeted therapies appropriate for personalized treatment of cancer patients based on these biomarkers.

近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Littlepage, L.E., Adler, A.S., Kouros-Mehr, H., Huang, G., Chou, J., Krig, S.R., Griffith, O.L., Korkola, J.E., Qu, K., Lawson, D.A., Xue, Q., Sternlicht, M.D., Dijkgraaf, G.J.P., Yaswen, P., Rugo, H.S., Sweeney, C.A., Collins, C.C., Gray, J., Chang, H.Y., Werb, Z. (2012) "The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression" Cancer Discovery; Jul;2(7):638-51. Epub 2012 May 10. Littlepage, LE, Sternlicht, MD, Rougier, N, Phillips, J, Gallo, E, Yu, Y, Williams, K, Brenot, A, Gordon, J, Werb, Z (2010) Matrix Metalloproteinases Contribute Distinct Roles in Neuroendocrine Prostate Carcinogenesis, Metastasis, and Angiogenesis Progression. Cancer Res. Mar 15;70(6):2224-34. Epub 2010 Mar 9. Kouros-Mehr, H, Bechis, SK, Slorach, EM, Littlepage, LE, Egeblad, M, Ewald, AJ, Pai, SY, Ho, IC, Werb, Z (2008) GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell. Feb;13(2):141-52. Adler, AS, Littlepage, LE, Lin, M, Kawahara, TLA, Wong, DJ, Liu, H, Werb, Z, Chang , HY (2008) CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Res. Jan 15;68(2):506-15. Egeblad, M, Littlepage, LE, Werb, Z (2005) The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol. 2005;70:383-8. Review. Radisky, DC, Levy, DD, Littlepage, LE, Liu, H, Nelson, CM, Fata, JE, Leake, D, Godden, EL, Albertson, DG, Nieto, MA, Werb, Z, Bissell, MJ (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. Jul 7; 436(7047): 123-7. Littlepage, LE, Egeblad, M, Werb, Z (2005) Coevolution of cancer and stromal cellular responses. Cancer Cell. Jun; 7(6): 499-500. Crane, R, Gadea, B, Littlepage, L, Wu, H, Ruderman, JV (2004) Aurora A, meiosis and mitosis. Biol Cell. Apr; 96(3):215-29. Review. Littlepage, LE, Wu, H, Andresson, T, Deanehan, JK, Amundadottir, L, Ruderman, JV (2002) Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proc Natl Acad Sci U S A. Nov 26; 99(24): 15440-5. Littlepage, LE and Ruderman, JV (2002) Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes & Dev. Sept. 1; 16(17): 2274-85. Huang, JN, Park, I, Ellingson, E, Littlepage, LE, Pellman, D (2001) Activity of the APC (Cdh1) form of the anaphase-promoting complex persists until S phase and prevents the premature expression of Cdc20p. J Cell Biol. Jul 9; 154(1): 85-94. Mendez, R, Hake, LE, Andresson, T, Littlepage, LE, Ruderman, JV, Richter, JD (2000) Phosphorylation of CPE binding factor by Eg2 regulates translation of c-mos mRNA. Nature. 404(6775): 302-7. Pasternack, LB, Littlepage, LE, Laude, DA, Appling, DR (1996) 13C NMR analysis of the use of alternative donors to the tetrahydrofolate-dependent one-carbon pools in Saccharomyces cerevisiae. Arch. Biochem. Biophys. 326(1): 158-165.